Cingulate (CING)

• Market cap: $55.2M
• 1 day: -4.15%
• 5 days: -12.05%
• 1 month: -11.68%
• 3 months: -36.39%
• 6 months: 14.92%
• Year to date: -5.02%
• 1 year: 4.26%
• 5 years: -99.61%
• 10 years: -99.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Employees: 14